Leila Chaychi, MD
Endocrinology · San Carlos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 4 carriers
- Office
- 1
- Since medical school
- 25 years
- Graduated 2001
Offices
1 location
Looking this up.
Hospitals listed: Ahmc Seton Medical Center · Community Hospital of the Monterey Peninsula · Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chaychi’s office at (650) 591-9933 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A127054 · Current
Licensed to practise in California · since 2013 · expires 2027-08-31 · Islamic Azad University, Tehran Medical Branch.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ahmc Seton Medical CenterDaly City, CAAcute Care Hospital · Proprietary · Has an emergency departmentPatients rate it 3 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Ahmc Seton Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.04) · 229 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.49 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.5 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.9 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.9 · 36 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 1,636 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 1,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.1 to 4.43) · 361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.62 (0 to 18.38) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.98 (1.71 to 10.25) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 73 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,387 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 30 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 77 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.4 · 53 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.4 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 63.8 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 258 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 48 cases | No different | Jan 2022 – Dec 2024 |
What patients said (257 patients answered, 20% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 59% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$342,544
Medicare paid this office $342,544 for 364 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 351 | $248,015 | $150 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 115 | $20,674 | $44 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 88 | $19,021 | $153 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 116 | $16,205 | $34 |
| Ultrasound scan of head and neck soft tissue | 94 | $11,468 | $114 |
See all 12 services
| Long return visit (40+ min) | 351 | $248,015 | $150 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 115 | $20,674 | $44 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 88 | $19,021 | $153 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 116 | $16,205 | $34 |
| Ultrasound scan of head and neck soft tissue | 94 | $11,468 | $114 |
| New patient visit (60+ min) | 50 | $9,085 | $182 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 32 | $4,287 | $130 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 36 | $2,979 | $51 |
| Return visit (30+ min) | 22 | $2,715 | $113 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 27 | $1,467 | $54 |
| Short return visit | 26 | $1,426 | $49 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 36 | $1,236 | $21 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 43 | 61 | 41 | 43 | 42 | 33 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 28 | 49 | 33 | 32 | 32 | 27 |
| Aspiration and/or injection of cyst of thyroid | 14 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
364 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 10% · Women 67% · Also on Medicaid 13% · Health risk score 1.19. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 72% · Diabetes 70% · Coronary heart disease 27% · Chronic kidney disease 27% · Depression 16% · Heart failure 12% · Atrial fibrillation 12% · Cancer 11% · COPD 10% · Dementia 5% · Stroke 5%.
The office billed $936,340, Medicare allowed $463,879 and paid $342,544; for 3,245 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 364 | 3,245 | 74 | 1.19 | $936,340 | $342,544 |
| 2023 | 372 | 6,525 | 74 | 1.23 | $934,478 | $399,273 |
| 2022 | 355 | 15,388 | 74 | 1.28 | $1,168,599 | $498,135 |
| 2021 | 348 | 6,017 | 74 | 1.38 | $938,039 | $411,887 |
| 2020 | 325 | 3,899 | 74 | 1.48 | $829,099 | $310,088 |
| 2019 | 356 | 3,913 | 74 | 1.34 | $882,061 | $320,904 |
| 2018 | 367 | 3,323 | 74 | 1.42 | $833,490 | $304,338 |
| 2017 | 368 | 1,337 | 74 | 1.49 | $409,233 | $147,186 |
| 2016 | 84 | 86 | 74 | 1.58 | $27,697 | $11,174 |
| 2013 | 181 | 549 | 72 | 1.60 | $71,600 | $24,240 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Long return visit (40+ min) | 365 | $259,426 | $156 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 117 | $25,555 | $151 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 137 | $18,420 | $46 |
| Ultrasound scan of head and neck soft tissue | 110 | $14,837 | $115 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 134 | $14,471 | $36 |
| Return visit (30+ min) | 66 | $10,975 | $116 |
| New patient visit (60+ min) | 53 | $9,964 | $188 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 39 | $5,475 | $130 |
| Short return visit | 54 | $3,698 | $49 |
| Short return visit (20+ min) | 22 | $1,877 | $85 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 30 | $1,764 | $55 |
| Injection of drug or substance under skin or into muscle | 22 | $829 | $12 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 17 | $647 | $31 |
| Photography of the retina | 15 | $544 | $36 |
2022: 17 services
| Long return visit (40+ min) | 344 | $254,520 | $156 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 149 | $41,544 | $155 |
| Injection, denosumab, 1 mg | 17 | $22,926 | None |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 168 | $17,435 | $45 |
| Ultrasound scan of head and neck soft tissue | 106 | $14,650 | $114 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 168 | $14,077 | $36 |
| Return visit (30+ min) | 66 | $13,235 | $115 |
| New patient visit (60+ min) | 49 | $9,649 | $197 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 106 | $7,899 | $51 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 150 | $7,823 | $30 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 42 | $5,675 | $132 |
| Short return visit | 56 | $4,120 | $51 |
| Short return visit (20+ min) | 23 | $2,046 | $76 |
| Injection of drug or substance under skin or into muscle | 38 | $1,932 | $13 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 32 | $1,770 | $55 |
| Photography of the retina | 24 | $1,018 | $36 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $696 | $22 |
2021: 17 services
| Long return visit (40+ min) | 341 | $248,183 | $163 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 143 | $39,260 | $166 |
| Return visit (30+ min) | 107 | $21,725 | $108 |
| Ultrasound scan of head and neck soft tissue | 105 | $16,592 | $119 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 142 | $13,165 | $52 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 169 | $11,358 | $32 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 120 | $11,347 | $50 |
| New patient visit (60+ min) | 47 | $8,222 | $175 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 37 | $5,571 | $136 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 67 | $2,848 | $39 |
| Short return visit | 35 | $2,202 | $54 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 31 | $1,879 | $57 |
| Short return visit (20+ min) | 18 | $1,641 | $82 |
| Photography of the retina | 32 | $1,264 | $38 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 14 | $949 | $68 |
| Injection of drug or substance under skin or into muscle | 16 | $516 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $419 | $23 |
2020: 12 services
| Long return visit (40+ min) | 297 | $147,593 | $129 |
| Return visit (30+ min) | 178 | $44,714 | $99 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 149 | $40,077 | $155 |
| Ultrasound scan of head and neck soft tissue | 113 | $18,413 | $117 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 134 | $14,087 | $51 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 165 | $10,710 | $32 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 52 | $7,249 | $119 |
| New patient visit (60+ min) | 28 | $5,418 | $193 |
| Short return visit (20+ min) | 54 | $4,714 | $67 |
| Photography of the retina | 53 | $2,758 | $45 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 45 | $2,651 | $54 |
| Short return visit | 32 | $1,589 | $43 |
2019: 15 services
| Long return visit (40+ min) | 325 | $153,677 | $127 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 198 | $60,045 | $158 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 173 | $21,640 | $48 |
| Ultrasound scan of head and neck soft tissue | 128 | $21,467 | $112 |
| Return visit (30+ min) | 104 | $15,257 | $91 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 197 | $12,041 | $32 |
| New patient visit (60+ min) | 43 | $7,173 | $167 |
| Photography of the retina | 111 | $6,996 | $49 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 38 | $5,156 | $120 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 25 | $1,544 | $55 |
| Short return visit | 32 | $1,444 | $44 |
| Short return visit (20+ min) | 19 | $1,411 | $67 |
| Aspiration and/or injection of cyst of thyroid | 14 | $915 | $65 |
| Injection of drug or substance under skin or into muscle | 26 | $693 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $478 | $23 |
2018: 13 services
| Long return visit (40+ min) | 315 | $129,601 | $124 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 205 | $42,610 | $49 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 177 | $42,500 | $159 |
| Ultrasound scan of head and neck soft tissue | 129 | $25,402 | $112 |
| Return visit (30+ min) | 126 | $19,793 | $89 |
| Photography of the retina | 114 | $9,856 | $57 |
| Fine needle aspiration using imaging guidance | 43 | $9,023 | $133 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 185 | $8,952 | $31 |
| New patient visit (60+ min) | 42 | $7,664 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,610 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,340 | $180 |
| Short return visit (20+ min) | 17 | $1,183 | $66 |
| Injection of drug or substance under skin or into muscle | 21 | $627 | $20 |
2017: 9 services
| Long return visit (40+ min) | 288 | $72,790 | $121 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 117 | $22,911 | $166 |
| Return visit (30+ min) | 190 | $22,717 | $84 |
| Ultrasound scan of head and neck soft tissue | 75 | $10,980 | $119 |
| New patient visit (60+ min) | 35 | $5,884 | $168 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 100 | $4,220 | $39 |
| Fine needle aspiration using imaging guidance | 21 | $3,182 | $138 |
| Short return visit (20+ min) | 20 | $1,018 | $51 |
| Injection of drug or substance under skin or into muscle | 15 | $429 | $21 |
2016: 1 service
| Long return visit (40+ min) | 70 | $9,508 | $134 |
2013: 8 services
| Short return visit (20+ min) | 112 | $8,267 | $60 |
| New patient visit (45+ min) | 40 | $5,281 | $132 |
| Return visit (30+ min) | 36 | $3,713 | $79 |
| Ultrasound scan of head and neck soft tissue | 20 | $1,942 | $88 |
| New patient visit (30+ min) | 17 | $1,597 | $94 |
| Hemoglobin a1c level | 63 | $863 | $13 |
| Insertion of needle into vein for collection of blood sample | 88 | $306 | $3 |
| Blood glucose (sugar) test performed by hand-held instrument | 78 | $297 | $3 |
Medicaid work
$19,433 in 2024
Medicaid paid $19,433 for 490 billed services this clinician did in 2024, up to 46 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 428 | $18,258 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 25 | $440 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording | 12 | $373 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 25 | $361 |
| 2024 | 490 | 4 | 46 | $19,433 |
| 2023 | 1,673 | 4 | 51 | $152,197 |
| 2022 | 1,897 | 6 | 65 | $142,240 |
| 2021 | 1,780 | 7 | 58 | $158,475 |
| 2020 | 1,635 | 8 | 56 | $136,841 |
| 2019 | 1,962 | 17 | 37 | $28,506 |
| 2018 | 1,435 | 17 | 35 | $15,593 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 1,033 | $128,744 |
| Telehealth originating site facility fee | 554 | $22,967 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 43 | $378 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 43 | $108 |
2022
| Long return visit (40+ min) | 1,088 | $121,701 |
| Telehealth originating site facility fee | 588 | $18,714 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 98 | $994 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 97 | $467 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording | 12 | $287 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 14 | $77 |
2021
| Long return visit (40+ min) | 1,047 | $134,983 |
| Telehealth originating site facility fee | 572 | $21,536 |
| Return visit (30+ min) | 31 | $967 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 30 | $369 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 51 | $303 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; each additional 20 minutes (List separately in addition to code for primary procedure) | 17 | $233 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 32 | $84 |
2020
| Long return visit (40+ min) | 854 | $113,759 |
| Telehealth originating site facility fee | 493 | $18,524 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording | 42 | $1,570 |
| Return visit (30+ min) | 99 | $1,190 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 63 | $808 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 58 | $476 |
| Measurement of vitamin D 25 hydroxy | 13 | $322 |
| Thyroid stimulating hormone (TSH) | 13 | $192 |
2019
| Measurement of vitamin D 25 hydroxy | 258 | $6,396 |
| Long return visit (40+ min) | 339 | $6,321 |
| Thyroid stimulating hormone (TSH) | 247 | $3,678 |
| COMPREHENSIVE METABOLIC PANEL | 183 | $1,680 |
| Measurement of free thyroxine | 208 | $1,639 |
| Blood test, lipids (cholesterol and triglycerides) | 131 | $1,512 |
| Hemoglobin A1C level | 177 | $1,503 |
| Measurement of total testosterone | 56 | $1,254 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording | 46 | $1,213 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 103 | $1,116 |
| Sex hormone binding globulin (SHBG) | 53 | $992 |
| Triiodothyronine T3; free | 26 | $389 |
2018
| Long return visit (40+ min) | 289 | $5,604 |
| Measurement of vitamin D 25 hydroxy | 102 | $2,529 |
| Thyroid stimulating hormone (TSH) | 151 | $2,214 |
| Hemoglobin A1C level | 112 | $939 |
| Measurement of free thyroxine | 116 | $918 |
| COMPREHENSIVE METABOLIC PANEL | 59 | $538 |
| Triiodothyronine T3; total (TT-3) | 42 | $529 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 378 | $499 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording | 12 | $460 |
| Return visit (30+ min) | 13 | $329 |
| Blood test, lipids (cholesterol and triglycerides) | 28 | $323 |
| Measurement of total testosterone | 13 | $296 |
Drugs they prescribed that Part D paid
$5,755,923
Pharmacies billed $5,755,923 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (12 of 5,925) in 2024. A higher opioid share than 9 in 10 peers; the typical endocrinology clinician is at 0%.
2,370 generic and 3,398 brand-name prescriptions · $5,755,923 in drug cost · 40 antibiotic prescriptions to 25 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Korlym | 32 | $1,765,346 | $55,167 |
| Mounjaro | 957 | $1,292,541 | $1,351 |
| Ozempic | 304 | $448,295 | $1,475 |
| Synjardy Xr | 261 | $318,490 | $1,220 |
| Jardiance | 170 | $190,778 | $1,122 |
See all 81 drugs
| Korlym | 32 | $1,765,346 | $55,167 |
| Mounjaro | 957 | $1,292,541 | $1,351 |
| Ozempic | 304 | $448,295 | $1,475 |
| Synjardy Xr | 261 | $318,490 | $1,220 |
| Jardiance | 170 | $190,778 | $1,122 |
| Tresiba Flextouch U-200 | 134 | $176,714 | $1,319 |
| Rybelsus | 83 | $144,379 | $1,740 |
| Synjardy | 111 | $120,037 | $1,081 |
| Trulicity | 49 | $73,159 | $1,493 |
| Farxiga | 62 | $65,778 | $1,061 |
| Kerendia | 54 | $46,542 | $862 |
| Synthroid | 372 | $36,827 | $99 |
| Invokamet Xr | 31 | $34,078 | $1,099 |
| Xigduo Xr | 18 | $27,297 | $1,517 |
| Tradjenta | 20 | $24,939 | $1,247 |
| Tresiba Flextouch U-100 | 44 | $24,268 | $552 |
| Toujeo Solostar | 13 | $23,064 | $1,774 |
| Invokamet | 19 | $22,737 | $1,197 |
| Fiasp Flextouch | 22 | $19,364 | $880 |
| Januvia | 14 | $15,573 | $1,112 |
| Invokana | 11 | $14,337 | $1,303 |
| Tirosint | 50 | $13,389 | $268 |
| Toujeo Max Solostar | 14 | $13,341 | $953 |
| Testosterone | 25 | $9,973 | $399 |
| Nano 2nd Gen Pen Needle | 59 | $5,499 | $93 |
| Lantus Solostar | 49 | $5,433 | $111 |
| Rosuvastatin | 181 | $4,643 | $26 |
| Novolog Flexpen | 22 | $4,607 | $209 |
| Insulin Aspart Flexpen | 19 | $4,224 | $222 |
| Levoxyl | 108 | $4,154 | $38 |
| Basaglar Kwikpen U-100 | 12 | $4,132 | $344 |
| Levemir Flexpen | 18 | $3,608 | $200 |
| Binosto | 12 | $3,434 | $286 |
| Thyquidity | 16 | $3,354 | $210 |
| Atorvastatin | 146 | $3,081 | $21 |
| Levothyroxine | 207 | $3,048 | $15 |
| Metformin | 146 | $2,730 | $19 |
| Liothyronine | 58 | $2,524 | $44 |
| Armour Thyroid | 16 | $2,509 | $157 |
| Ezetimibe | 62 | $2,499 | $40 |
| Estradiol (Twice Weekly) | 20 | $2,005 | $100 |
| Fenofibrate | 21 | $1,899 | $90 |
| Losartan | 170 | $1,732 | $10 |
| Calcitriol | 85 | $1,667 | $20 |
| Ultra-Fine Short Pen Needle | 18 | $1,641 | $91 |
| Metformin Hcl Er | 123 | $1,396 | $11 |
| Methimazole | 78 | $1,198 | $15 |
| Fluconazole | 14 | $1,140 | $81 |
| Gabapentin | 55 | $953 | $17 |
| Duloxetine | 18 | $845 | $47 |
| Ondansetron | 21 | $801 | $38 |
| Simvastatin | 42 | $765 | $18 |
| Spironolactone | 61 | $738 | $12 |
| Omeprazole | 36 | $714 | $20 |
| Pioglitazone | 47 | $694 | $15 |
| Progesterone | 23 | $692 | $30 |
| Alendronate | 60 | $553 | $9 |
| Hydrocortisone | 20 | $511 | $26 |
| Cabergoline | 16 | $489 | $31 |
| Zolpidem | 16 | $425 | $27 |
| Potassium Chloride | 12 | $391 | $33 |
| Topiramate | 37 | $379 | $10 |
| Ondansetron Odt | 20 | $334 | $17 |
| Vitamin D2 | 11 | $299 | $27 |
| Pantoprazole | 20 | $273 | $14 |
| Pravastatin | 22 | $258 | $12 |
| Lisinopril | 54 | $237 | $4 |
| Benazepril | 17 | $229 | $13 |
| Amlodipine Besylate | 50 | $177 | $4 |
| Fludrocortisone Acetate | 12 | $163 | $14 |
| Olmesartan Medoxomil | 15 | $145 | $10 |
| Norethindron-Ethinyl Estradiol | 14 | $138 | $10 |
| Azithromycin | 19 | $120 | $6 |
| Lisinopril-Hydrochlorothiazide | 14 | $111 | $8 |
| Hydrochlorothiazide | 17 | $108 | $6 |
| Enalapril Maleate | 12 | $102 | $9 |
| Trazodone | 18 | $91 | $5 |
| Triamcinolone Acetonide | 11 | $72 | $7 |
| Allopurinol | 12 | $38 | $3 |
| Tramadol | 12 | $29 | $2 |
| Fluoxetine | 15 | $6 | $0 |
Year by year
| 2024 | 5,925 | 431 | 0% (12) | 57% | $5,755,923 |
| 2023 | 4,862 | 401 | None | 54% | $4,885,352 |
| 2022 | 4,697 | 388 | None | 49% | $4,795,277 |
| 2021 | 4,567 | 368 | 0% (16) | 50% | $3,701,717 |
| 2020 | 4,442 | 345 | 0% (15) | 49% | $3,538,656 |
| 2019 | 4,558 | 353 | None | 55% | $2,918,144 |
| 2018 | 4,518 | 368 | None | 57% | $1,946,758 |
| 2017 | 5,046 | 416 | 0% (0) | 59% | $1,799,579 |
| 2016 | 4,110 | 396 | 0% (0) | 58% | $1,371,604 |
| 2015 | 3,282 | 291 | 0% (0) | 59% | $961,669 |
| 2014 | 1,751 | 302 | 0% (0) | 57% | $414,882 |
| 2013 | 829 | 200 | 0% (0) | 65% | $154,636 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 71 drugs
| Korlym | 37 | $1,848,869 | $49,969 |
| Ozempic | 402 | $599,018 | $1,490 |
| Mounjaro | 226 | $346,032 | $1,531 |
| Synjardy Xr | 257 | $307,126 | $1,195 |
| Trulicity | 119 | $197,851 | $1,663 |
| Rybelsus | 86 | $165,817 | $1,928 |
| Jardiance | 116 | $153,663 | $1,325 |
| Tresiba Flextouch U-200 | 141 | $147,913 | $1,049 |
| Synjardy | 103 | $100,733 | $978 |
| Farxiga | 51 | $70,138 | $1,375 |
| Xigduo Xr | 35 | $47,776 | $1,365 |
| Invokamet Xr | 37 | $42,166 | $1,140 |
| Kerendia | 29 | $35,523 | $1,225 |
| Synthroid | 356 | $33,969 | $95 |
| Tresiba Flextouch U-100 | 53 | $28,192 | $532 |
| Tradjenta | 23 | $27,741 | $1,206 |
| Afrezza | 13 | $24,628 | $1,894 |
| Invokamet | 25 | $23,376 | $935 |
| Novolog Flexpen | 22 | $21,188 | $963 |
| Fiasp Flextouch | 20 | $21,053 | $1,053 |
| Invokana | 17 | $18,266 | $1,074 |
| Januvia | 11 | $16,124 | $1,466 |
| Toujeo Max Solostar | 11 | $12,439 | $1,131 |
| Tirosint | 38 | $11,487 | $302 |
| Lantus Solostar | 23 | $11,228 | $488 |
| Praluent | 13 | $11,052 | $850 |
| Omnipod 5 G6 Pods (Gen 5) | 12 | $10,635 | $886 |
| Levemir Flexpen | 11 | $10,496 | $954 |
| Novolog | 11 | $8,765 | $797 |
| Insulin Aspart Flexpen | 15 | $8,335 | $556 |
| Glyxambi | 11 | $7,329 | $666 |
| Levothyroxine | 259 | $5,252 | $20 |
| Rosuvastatin | 160 | $4,822 | $30 |
| Nano 2nd Gen Pen Needle | 51 | $4,787 | $94 |
| Thyquidity | 16 | $4,277 | $267 |
| Ezetimibe | 62 | $4,119 | $66 |
| Metformin | 184 | $3,527 | $19 |
| Calcitriol | 84 | $2,959 | $35 |
| Atorvastatin | 120 | $2,838 | $24 |
| Insulin Glargine-Yfgn | 14 | $2,334 | $167 |
| Losartan | 123 | $2,042 | $17 |
| Fenofibrate | 29 | $1,907 | $66 |
| Metformin Hcl Er | 115 | $1,577 | $14 |
| Liothyronine | 35 | $1,551 | $44 |
| Ultra-Fine Short Pen Needle | 18 | $1,550 | $86 |
| Hydrocortisone | 28 | $1,337 | $48 |
| Levoxyl | 40 | $1,308 | $33 |
| Pioglitazone | 59 | $1,107 | $19 |
| Spironolactone | 53 | $1,097 | $21 |
| Gabapentin | 38 | $1,061 | $28 |
| Methimazole | 72 | $937 | $13 |
| Alendronate | 63 | $772 | $12 |
| Duloxetine | 17 | $757 | $45 |
| Fluconazole | 18 | $699 | $39 |
| Valsartan | 14 | $614 | $44 |
| Cabergoline | 13 | $587 | $45 |
| Lisinopril | 42 | $570 | $14 |
| Omeprazole | 26 | $477 | $18 |
| Amlodipine Besylate | 34 | $445 | $13 |
| Simvastatin | 38 | $382 | $10 |
| Benazepril | 19 | $371 | $20 |
| Topiramate | 24 | $303 | $13 |
| Lovastatin | 12 | $297 | $25 |
| Zolpidem | 13 | $290 | $22 |
| Pravastatin | 12 | $282 | $24 |
| Ondansetron | 11 | $280 | $25 |
| Norethindron-Ethinyl Estradiol | 18 | $186 | $10 |
| Lisinopril-Hydrochlorothiazide | 12 | $172 | $14 |
| Fludrocortisone Acetate | 11 | $166 | $15 |
| Pantoprazole | 11 | $154 | $14 |
| Trazodone | 18 | $121 | $7 |
2022: 74 drugs
| Korlym | 39 | $1,827,130 | $46,849 |
| Strensiq | 14 | $798,197 | $57,014 |
| Trulicity | 227 | $386,695 | $1,704 |
| Ozempic | 187 | $260,292 | $1,392 |
| Synjardy Xr | 208 | $207,901 | $1,000 |
| Tresiba Flextouch U-200 | 132 | $154,033 | $1,167 |
| Jardiance | 148 | $140,568 | $950 |
| Synjardy | 124 | $125,009 | $1,008 |
| Rybelsus | 65 | $103,089 | $1,586 |
| Farxiga | 49 | $64,991 | $1,326 |
| Mounjaro | 30 | $42,827 | $1,428 |
| Xigduo Xr | 51 | $41,698 | $818 |
| Invokamet | 41 | $40,338 | $984 |
| Invokamet Xr | 45 | $39,791 | $884 |
| Bydureon Bcise | 17 | $33,822 | $1,990 |
| Tradjenta | 26 | $27,904 | $1,073 |
| Tresiba Flextouch U-100 | 42 | $25,976 | $618 |
| Synthroid | 303 | $25,537 | $84 |
| Lantus Solostar | 47 | $20,461 | $435 |
| Victoza 3-Pak | 15 | $20,032 | $1,335 |
| Januvia | 17 | $19,794 | $1,164 |
| Fiasp Flextouch | 21 | $19,290 | $919 |
| Trijardy Xr | 11 | $18,035 | $1,640 |
| Invokana | 23 | $14,618 | $636 |
| Kerendia | 11 | $13,343 | $1,213 |
| Novolog Flexpen | 16 | $11,808 | $738 |
| Levemir Flextouch | 14 | $11,588 | $828 |
| Tirosint | 50 | $11,449 | $229 |
| Testosterone | 13 | $10,890 | $838 |
| Jentadueto | 12 | $9,308 | $776 |
| Insulin Aspart Flexpen | 29 | $9,099 | $314 |
| Metformin Er Osmotic | 16 | $5,574 | $348 |
| Nano 2nd Gen Pen Needle | 54 | $5,420 | $100 |
| Rosuvastatin | 176 | $5,259 | $30 |
| Ezetimibe | 66 | $4,494 | $68 |
| Liothyronine | 38 | $4,123 | $108 |
| Levothyroxine | 253 | $4,087 | $16 |
| Thyquidity | 17 | $2,734 | $161 |
| Metformin | 208 | $2,648 | $13 |
| Atorvastatin | 112 | $2,588 | $23 |
| Losartan | 151 | $2,477 | $16 |
| Ultra-Fine Short Pen Needle | 21 | $2,381 | $113 |
| Calcitriol | 64 | $2,256 | $35 |
| Spironolactone | 80 | $1,776 | $22 |
| Metformin Hcl Er | 106 | $1,627 | $15 |
| Ultra-Fine Nano Pen Needle | 19 | $1,267 | $67 |
| Hydrocortisone | 27 | $1,259 | $47 |
| Armour Thyroid | 21 | $1,197 | $57 |
| Pioglitazone | 55 | $1,058 | $19 |
| Gabapentin | 41 | $1,057 | $26 |
| Lisinopril | 74 | $968 | $13 |
| Alendronate | 84 | $868 | $10 |
| Duloxetine | 11 | $842 | $77 |
| Insulin | 11 | $764 | $69 |
| Fenofibrate | 19 | $730 | $38 |
| Methimazole | 59 | $686 | $12 |
| Estradiol | 11 | $651 | $59 |
| Levoxyl | 22 | $631 | $29 |
| Valsartan | 23 | $620 | $27 |
| Amlodipine Besylate | 32 | $605 | $19 |
| Cabergoline | 13 | $562 | $43 |
| Topiramate | 58 | $488 | $8 |
| Fenofibrate | 16 | $429 | $27 |
| Fluconazole | 16 | $402 | $25 |
| Simvastatin | 41 | $377 | $9 |
| Bupropion Hcl Sr | 12 | $365 | $30 |
| Zolpidem | 17 | $304 | $18 |
| Benazepril | 15 | $284 | $19 |
| Omeprazole | 18 | $258 | $14 |
| Fludrocortisone Acetate | 14 | $251 | $18 |
| Metoprolol | 14 | $237 | $17 |
| Lisinopril-Hydrochlorothiazide | 12 | $130 | $11 |
| Norethindron-Ethinyl Estradiol | 17 | $118 | $7 |
| Hydrochlorothiazide | 12 | $105 | $9 |
2021: 71 drugs
| Korlym | 43 | $1,739,912 | $40,463 |
| Trulicity | 311 | $407,380 | $1,310 |
| Tresiba Flextouch U-200 | 136 | $157,389 | $1,157 |
| Synjardy Xr | 152 | $132,863 | $874 |
| Jardiance | 138 | $124,580 | $903 |
| Synjardy | 141 | $123,868 | $878 |
| Ozempic | 87 | $114,846 | $1,320 |
| Farxiga | 60 | $64,348 | $1,072 |
| Rybelsus | 41 | $59,274 | $1,446 |
| Invokamet | 54 | $57,021 | $1,056 |
| Forteo | 12 | $47,605 | $3,967 |
| Xigduo Xr | 54 | $47,072 | $872 |
| Bydureon Bcise | 29 | $45,483 | $1,568 |
| Victoza 3-Pak | 23 | $39,420 | $1,714 |
| Januvia | 36 | $37,196 | $1,033 |
| Tradjenta | 42 | $36,169 | $861 |
| Lantus Solostar | 62 | $35,369 | $570 |
| Invokamet Xr | 37 | $35,047 | $947 |
| Invokana | 34 | $29,731 | $874 |
| Tresiba Flextouch U-100 | 39 | $24,126 | $619 |
| Synthroid | 239 | $20,326 | $85 |
| Levemir Flextouch | 26 | $18,431 | $709 |
| Prolia | 13 | $17,742 | $1,365 |
| Tirosint | 67 | $13,902 | $207 |
| Testosterone | 17 | $12,807 | $753 |
| Fiasp Flextouch | 23 | $12,318 | $536 |
| Jentadueto | 11 | $10,599 | $964 |
| Lantus | 20 | $9,684 | $484 |
| Novolog Flexpen | 17 | $9,053 | $533 |
| Insulin Aspart Flexpen | 17 | $6,365 | $374 |
| Praluent | 12 | $5,851 | $488 |
| Rosuvastatin | 188 | $5,381 | $29 |
| Levothyroxine | 243 | $5,114 | $21 |
| Nano 2nd Gen Pen Needle | 47 | $3,919 | $83 |
| Liothyronine | 50 | $3,186 | $64 |
| Metformin | 220 | $2,972 | $14 |
| Calcitriol | 61 | $2,923 | $48 |
| Ultra-Fine Nano Pen Needle | 33 | $2,639 | $80 |
| Atorvastatin | 121 | $2,584 | $21 |
| Ezetimibe | 55 | $2,488 | $45 |
| Losartan | 134 | $2,057 | $15 |
| Hydrocortisone | 31 | $1,618 | $52 |
| Metformin Hcl Er | 75 | $1,423 | $19 |
| Spironolactone | 74 | $1,402 | $19 |
| Ultra-Fine Short Pen Needle | 14 | $1,344 | $96 |
| Fenofibrate | 22 | $1,297 | $59 |
| Valsartan | 30 | $1,237 | $41 |
| Pioglitazone | 47 | $1,084 | $23 |
| Fenofibrate | 20 | $992 | $50 |
| Ultra-Fine Mini Pen Needle | 18 | $964 | $54 |
| Lisinopril | 68 | $913 | $13 |
| Gabapentin | 45 | $905 | $20 |
| Fluconazole | 21 | $825 | $39 |
| Alendronate | 66 | $782 | $12 |
| Simvastatin | 36 | $665 | $18 |
| Omeprazole | 26 | $639 | $25 |
| Levoxyl | 14 | $623 | $44 |
| Droplet Pen Needle | 18 | $620 | $34 |
| Cabergoline | 13 | $616 | $47 |
| Methimazole | 71 | $562 | $8 |
| Amlodipine Besylate | 32 | $514 | $16 |
| Topiramate | 41 | $490 | $12 |
| Pravastatin | 22 | $481 | $22 |
| Zolpidem | 17 | $341 | $20 |
| Benazepril | 14 | $263 | $19 |
| Losartan-Hydrochlorothiazide | 11 | $257 | $23 |
| Bupropion Hcl Sr | 13 | $248 | $19 |
| Lisinopril-Hydrochlorothiazide | 12 | $229 | $19 |
| Hydrochlorothiazide | 20 | $165 | $8 |
| Norethindron-Ethinyl Estradiol | 14 | $98 | $7 |
| Glipizide | 15 | $84 | $6 |
2020: 71 drugs
| Korlym | 49 | $1,756,993 | $35,857 |
| Trulicity | 236 | $304,544 | $1,290 |
| Tresiba Flextouch U-200 | 105 | $136,718 | $1,302 |
| Ozempic | 82 | $108,486 | $1,323 |
| Synjardy | 137 | $104,226 | $761 |
| Synjardy Xr | 121 | $97,784 | $808 |
| Victoza 3-Pak | 52 | $93,623 | $1,800 |
| Jardiance | 116 | $90,409 | $779 |
| Invokamet | 78 | $86,141 | $1,104 |
| Farxiga | 60 | $52,894 | $882 |
| Invokamet Xr | 55 | $48,921 | $889 |
| Invokana | 55 | $44,784 | $814 |
| Bydureon Bcise | 33 | $44,058 | $1,335 |
| Tradjenta | 60 | $40,714 | $679 |
| Xigduo Xr | 41 | $34,430 | $840 |
| Lantus Solostar | 60 | $31,962 | $533 |
| Januvia | 24 | $24,865 | $1,036 |
| Levemir Flextouch | 32 | $24,206 | $756 |
| Rybelsus | 19 | $18,921 | $996 |
| Novolog Flexpen | 30 | $17,743 | $591 |
| Synthroid | 206 | $17,679 | $86 |
| Prolia | 13 | $16,678 | $1,283 |
| Tresiba Flextouch U-100 | 27 | $15,947 | $591 |
| Soliqua 100-33 | 12 | $14,544 | $1,212 |
| Lantus | 31 | $14,312 | $462 |
| Jentadueto | 21 | $14,145 | $674 |
| Fiasp Flextouch | 20 | $13,902 | $695 |
| Testosterone | 24 | $10,869 | $453 |
| Tirosint | 61 | $10,134 | $166 |
| Dexilant | 16 | $9,430 | $589 |
| Praluent | 13 | $6,268 | $482 |
| Rosuvastatin | 156 | $5,551 | $36 |
| Ultra-Fine Nano Pen Needle | 67 | $5,443 | $81 |
| Levothyroxine | 243 | $5,039 | $21 |
| Calcitriol | 44 | $2,701 | $61 |
| Liothyronine | 36 | $2,633 | $73 |
| Metformin | 264 | $2,393 | $9 |
| Nano 2nd Gen Pen Needle | 25 | $1,987 | $79 |
| Metformin Hcl Er | 105 | $1,929 | $18 |
| Atorvastatin | 114 | $1,615 | $14 |
| Pioglitazone | 73 | $1,490 | $20 |
| Losartan | 130 | $1,411 | $11 |
| Spironolactone | 70 | $1,379 | $20 |
| Hydrocortisone | 33 | $1,253 | $38 |
| Ezetimibe | 29 | $1,160 | $40 |
| Fluconazole | 39 | $1,117 | $29 |
| Ultra-Fine Mini Pen Needle | 21 | $1,080 | $51 |
| Lisinopril | 79 | $1,017 | $13 |
| Fenofibrate | 23 | $1,013 | $44 |
| Ultra-Fine Short Pen Needle | 15 | $885 | $59 |
| Valsartan | 16 | $848 | $53 |
| Gabapentin | 44 | $824 | $19 |
| Levoxyl | 13 | $749 | $58 |
| Simvastatin | 44 | $720 | $16 |
| Cabergoline | 13 | $646 | $50 |
| Methimazole | 54 | $635 | $12 |
| Alendronate | 44 | $622 | $14 |
| Estradiol | 11 | $543 | $49 |
| Zolpidem | 28 | $443 | $16 |
| Glipizide Er | 13 | $423 | $33 |
| Amlodipine Besylate | 40 | $421 | $11 |
| Metoprolol | 16 | $388 | $24 |
| Valacyclovir | 12 | $377 | $31 |
| Droplet Pen Needle | 11 | $373 | $34 |
| Irbesartan | 11 | $368 | $33 |
| Pravastatin | 20 | $366 | $18 |
| Omeprazole | 25 | $338 | $14 |
| Norethindron-Ethinyl Estradiol | 16 | $249 | $16 |
| Losartan-Hydrochlorothiazide | 12 | $219 | $18 |
| Tramadol Hcl-Acetaminophen | 11 | $134 | $12 |
| Hydrochlorothiazide | 21 | $103 | $5 |
2019: 66 drugs
| Korlym | 42 | $1,103,665 | $26,278 |
| Trulicity | 335 | $372,718 | $1,113 |
| Tresiba Flextouch U-200 | 190 | $217,514 | $1,145 |
| Invokamet | 135 | $114,625 | $849 |
| Victoza 3-Pak | 72 | $103,071 | $1,432 |
| Jardiance | 127 | $97,342 | $766 |
| Synjardy | 143 | $95,545 | $668 |
| Synjardy Xr | 90 | $79,553 | $884 |
| Invokamet Xr | 75 | $54,375 | $725 |
| Farxiga | 75 | $53,765 | $717 |
| Bydureon Bcise | 42 | $46,247 | $1,101 |
| Lantus Solostar | 89 | $40,484 | $455 |
| Januvia | 45 | $37,584 | $835 |
| Tradjenta | 43 | $31,386 | $730 |
| Invokana | 38 | $29,795 | $784 |
| Novolog Flexpen | 34 | $22,997 | $676 |
| Synthroid | 323 | $21,353 | $66 |
| Xigduo Xr | 34 | $20,684 | $608 |
| Levemir Flextouch | 33 | $20,285 | $615 |
| Ozempic | 18 | $18,059 | $1,003 |
| Soliqua 100-33 | 15 | $17,549 | $1,170 |
| Lantus | 36 | $16,411 | $456 |
| Bydureon | 14 | $15,905 | $1,136 |
| Tresiba Flextouch U-100 | 27 | $15,189 | $563 |
| Novolog | 25 | $14,100 | $564 |
| Humalog Kwikpen U-100 | 26 | $13,851 | $533 |
| Testosterone | 20 | $11,605 | $580 |
| Jentadueto | 15 | $10,050 | $670 |
| Ultra-Fine Nano Pen Needle | 98 | $7,431 | $76 |
| Tirosint | 40 | $6,800 | $170 |
| Potassium Chloride | 11 | $4,363 | $397 |
| Rosuvastatin | 116 | $3,254 | $28 |
| Levothyroxine | 146 | $3,023 | $21 |
| Calcitriol | 34 | $2,116 | $62 |
| Liothyronine | 37 | $2,010 | $54 |
| Metformin | 211 | $1,842 | $9 |
| Metformin Hcl Er | 97 | $1,721 | $18 |
| Ezetimibe | 42 | $1,720 | $41 |
| Atorvastatin | 97 | $1,599 | $16 |
| Hydrocortisone | 45 | $1,317 | $29 |
| Fenofibrate | 21 | $1,197 | $57 |
| Spironolactone | 68 | $1,170 | $17 |
| Losartan | 117 | $1,000 | $9 |
| Cabergoline | 13 | $968 | $74 |
| Fluconazole | 34 | $962 | $28 |
| Methimazole | 79 | $897 | $11 |
| Valsartan | 24 | $896 | $37 |
| Easy Comfort Pen Needles | 11 | $882 | $80 |
| Repaglinide | 18 | $822 | $46 |
| Lisinopril | 111 | $755 | $7 |
| Ultra-Fine Short Pen Needle | 12 | $700 | $58 |
| Simvastatin | 65 | $662 | $10 |
| Gabapentin | 53 | $586 | $11 |
| Alendronate | 64 | $547 | $9 |
| Levoxyl | 13 | $530 | $41 |
| Pioglitazone | 37 | $514 | $14 |
| Amlodipine Besylate | 33 | $443 | $13 |
| Zolpidem | 28 | $389 | $14 |
| Irbesartan | 17 | $386 | $23 |
| Glipizide Er | 15 | $385 | $26 |
| Omeprazole | 23 | $285 | $12 |
| Pravastatin | 17 | $216 | $13 |
| Fludrocortisone Acetate | 14 | $186 | $13 |
| Hydrochlorothiazide | 31 | $177 | $6 |
| Norethindron-Ethinyl Estradiol | 18 | $153 | $9 |
| Benazepril | 11 | $135 | $12 |
2018: 74 drugs
| Trulicity | 254 | $277,775 | $1,094 |
| Tresiba Flextouch U-200 | 209 | $183,217 | $877 |
| Invokamet | 198 | $146,968 | $742 |
| Victoza 3-Pak | 57 | $77,260 | $1,355 |
| Jardiance | 110 | $76,966 | $700 |
| Synjardy | 114 | $72,220 | $634 |
| Invokamet Xr | 105 | $71,787 | $684 |
| Lantus Solostar | 108 | $53,069 | $491 |
| Januvia | 61 | $49,675 | $814 |
| Synjardy Xr | 79 | $45,843 | $580 |
| Invokana | 59 | $45,482 | $771 |
| Tradjenta | 52 | $37,646 | $724 |
| Tanzeum | 40 | $37,330 | $933 |
| Forteo | 11 | $36,085 | $3,280 |
| Farxiga | 54 | $36,058 | $668 |
| Novolog | 47 | $31,421 | $669 |
| Humalog Kwikpen U-100 | 41 | $23,997 | $585 |
| Synthroid | 393 | $22,559 | $57 |
| Xultophy 100-3.6 | 17 | $21,798 | $1,282 |
| Tresiba Flextouch U-100 | 39 | $21,351 | $547 |
| Jentadueto | 36 | $21,109 | $586 |
| Humalog | 17 | $19,309 | $1,136 |
| Bydureon Bcise | 24 | $18,570 | $774 |
| Metformin Er Osmotic | 26 | $18,328 | $705 |
| Novolog Flexpen | 23 | $17,627 | $766 |
| Levemir Flextouch | 24 | $17,156 | $715 |
| Lantus | 41 | $17,017 | $415 |
| Soliqua 100-33 | 13 | $10,290 | $792 |
| Janumet Xr | 16 | $10,154 | $635 |
| Basaglar Kwikpen U-100 | 20 | $9,003 | $450 |
| Toujeo Solostar | 12 | $8,873 | $739 |
| Ultra-Fine Nano Pen Needle | 125 | $8,411 | $67 |
| Testosterone | 13 | $7,291 | $561 |
| Tirosint | 39 | $6,214 | $159 |
| Apidra | 12 | $5,632 | $469 |
| Cabergoline | 13 | $2,828 | $218 |
| Atorvastatin | 121 | $2,528 | $21 |
| Ezetimibe | 25 | $2,399 | $96 |
| Metformin | 234 | $2,399 | $10 |
| Liothyronine | 44 | $2,375 | $54 |
| Levothyroxine | 109 | $2,296 | $21 |
| Rosuvastatin | 68 | $2,271 | $33 |
| Calcitriol | 30 | $1,821 | $61 |
| Pioglitazone | 27 | $1,821 | $67 |
| Ultra-Fine Short Pen Needle | 25 | $1,727 | $69 |
| Valsartan | 25 | $1,624 | $65 |
| Metformin Hcl Er | 88 | $1,280 | $15 |
| Repaglinide | 21 | $1,157 | $55 |
| Losartan | 114 | $1,132 | $10 |
| Ultra-Fine Mini Pen Needle | 22 | $1,076 | $49 |
| Simvastatin | 71 | $942 | $13 |
| Spironolactone | 55 | $768 | $14 |
| Methimazole | 67 | $702 | $10 |
| Glipizide Er | 25 | $645 | $26 |
| Alendronate | 70 | $622 | $9 |
| Gabapentin | 51 | $588 | $12 |
| Hydrocortisone | 27 | $588 | $22 |
| Insulin | 11 | $585 | $53 |
| Lisinopril | 87 | $527 | $6 |
| Metoprolol | 14 | $522 | $37 |
| Fluconazole | 13 | $504 | $39 |
| Zolpidem | 23 | $433 | $19 |
| Norethindron-Ethinyl Estradiol | 16 | $350 | $22 |
| Irbesartan | 13 | $311 | $24 |
| Lovastatin | 25 | $293 | $12 |
| Pravastatin | 17 | $267 | $16 |
| Omeprazole | 15 | $217 | $14 |
| Losartan-Hydrochlorothiazide | 11 | $180 | $16 |
| Fludrocortisone Acetate | 19 | $178 | $9 |
| Amlodipine Besylate | 14 | $165 | $12 |
| Benazepril | 15 | $149 | $10 |
| Glipizide | 13 | $118 | $9 |
| Dexamethasone | 25 | $47 | $2 |
| Hydrochlorothiazide | 21 | $47 | $2 |
2017: 67 drugs
| Trulicity | 290 | $253,551 | $874 |
| Invokamet | 274 | $176,508 | $644 |
| Tresiba Flextouch U-200 | 217 | $160,059 | $738 |
| Victoza 3-Pak | 85 | $97,381 | $1,146 |
| Invokana | 148 | $91,507 | $618 |
| Lantus Solostar | 188 | $89,704 | $477 |
| Forteo | 22 | $64,559 | $2,935 |
| Januvia | 103 | $62,447 | $606 |
| Synjardy | 111 | $60,314 | $543 |
| Jardiance | 98 | $55,064 | $562 |
| Invokamet Xr | 99 | $55,024 | $556 |
| Tanzeum | 54 | $50,627 | $938 |
| Tradjenta | 76 | $45,109 | $594 |
| Levemir Flextouch | 68 | $42,396 | $623 |
| Lantus | 64 | $35,900 | $561 |
| Novolog | 46 | $35,545 | $773 |
| Jentadueto | 60 | $35,456 | $591 |
| Novolog Flexpen | 48 | $34,967 | $728 |
| Metformin Hcl Er | 137 | $29,455 | $215 |
| Humalog Kwikpen U-100 | 49 | $26,619 | $543 |
| Tresiba Flextouch U-100 | 38 | $20,335 | $535 |
| Synthroid | 388 | $20,282 | $52 |
| Androgel | 14 | $16,480 | $1,177 |
| Janumet | 24 | $14,279 | $595 |
| Prolia | 12 | $13,054 | $1,088 |
| Humalog | 18 | $11,835 | $657 |
| Soliqua 100-33 | 16 | $11,702 | $731 |
| Janumet Xr | 20 | $8,494 | $425 |
| Ultra-Fine Nano Pen Needle | 111 | $7,051 | $64 |
| Kombiglyze Xr | 12 | $6,160 | $513 |
| Rosuvastatin | 81 | $5,918 | $73 |
| Tirosint | 48 | $5,859 | $122 |
| Ezetimibe | 25 | $4,842 | $194 |
| Levothyroxine | 129 | $2,943 | $23 |
| Metformin | 303 | $2,794 | $9 |
| Atorvastatin | 133 | $2,686 | $20 |
| Ultra-Fine Short Pen Needle | 27 | $2,093 | $78 |
| Calcitriol | 47 | $1,832 | $39 |
| Repaglinide | 37 | $1,790 | $48 |
| Valsartan | 41 | $1,774 | $43 |
| Pioglitazone | 31 | $1,410 | $45 |
| Liothyronine | 38 | $1,392 | $37 |
| Ultra-Fine Mini Pen Needle | 27 | $1,334 | $49 |
| Bd Ultra-Fine Pen Needle | 19 | $1,242 | $65 |
| Losartan | 110 | $1,066 | $10 |
| Novofine 32 | 15 | $989 | $66 |
| Insulin | 13 | $950 | $73 |
| Simvastatin | 69 | $901 | $13 |
| Insulin | 21 | $811 | $39 |
| Metoprolol | 27 | $791 | $29 |
| Methimazole | 79 | $689 | $9 |
| Levoxyl | 18 | $683 | $38 |
| Fluconazole | 22 | $623 | $28 |
| Gabapentin | 45 | $611 | $14 |
| Spironolactone | 52 | $547 | $11 |
| Lisinopril | 94 | $525 | $6 |
| Alendronate | 65 | $462 | $7 |
| Enalapril Maleate | 12 | $454 | $38 |
| Lovastatin | 25 | $339 | $14 |
| Hydrocortisone | 15 | $336 | $22 |
| Glipizide | 41 | $296 | $7 |
| Glipizide Er | 18 | $290 | $16 |
| Prednisone | 24 | $192 | $8 |
| Amlodipine Besylate | 20 | $169 | $8 |
| Fludrocortisone Acetate | 13 | $105 | $8 |
| Microgestin | 11 | $83 | $8 |
| Hydrochlorothiazide | 14 | $49 | $4 |
2016: 58 drugs
| Invokamet | 314 | $172,661 | $550 |
| Lantus Solostar | 242 | $134,686 | $557 |
| Invokana | 212 | $111,112 | $524 |
| Trulicity | 146 | $107,268 | $735 |
| Januvia | 156 | $84,650 | $543 |
| Victoza 3-Pak | 73 | $71,618 | $981 |
| Metformin Hcl Er | 108 | $64,676 | $599 |
| Levemir Flextouch | 91 | $64,245 | $706 |
| Tradjenta | 92 | $54,798 | $596 |
| Jentadueto | 100 | $48,661 | $487 |
| Janumet | 87 | $47,183 | $542 |
| Lantus | 75 | $37,238 | $497 |
| Tresiba Flextouch U-200 | 48 | $35,647 | $743 |
| Novolog Flexpen | 47 | $35,436 | $754 |
| Levemir | 31 | $18,088 | $583 |
| Tanzeum | 19 | $15,873 | $835 |
| Crestor | 38 | $15,744 | $414 |
| Jardiance | 31 | $15,055 | $486 |
| Humalog Kwikpen U-100 | 25 | $13,543 | $542 |
| Humalog | 17 | $11,916 | $701 |
| Janumet Xr | 26 | $10,375 | $399 |
| Bd Ultra-Fine Pen Needle | 175 | $10,351 | $59 |
| Novolog | 20 | $9,922 | $496 |
| Zetia | 35 | $9,868 | $282 |
| Synthroid | 207 | $9,153 | $44 |
| Kombiglyze Xr | 23 | $8,915 | $388 |
| Synjardy | 14 | $8,324 | $595 |
| Glyxambi | 13 | $6,823 | $525 |
| Victoza 2-Pak | 12 | $5,797 | $483 |
| Rosuvastatin | 19 | $2,439 | $128 |
| Valsartan | 16 | $2,426 | $152 |
| Metformin | 248 | $2,292 | $9 |
| Tirosint | 13 | $2,195 | $169 |
| Levothyroxine | 108 | $2,194 | $20 |
| Repaglinide | 25 | $1,463 | $59 |
| Atorvastatin | 100 | $1,445 | $14 |
| Methimazole | 73 | $931 | $13 |
| Insulin | 21 | $834 | $40 |
| Losartan | 106 | $819 | $8 |
| Glipizide Er | 46 | $795 | $17 |
| Novofine 32 | 13 | $722 | $56 |
| Novotwist | 14 | $664 | $47 |
| Metoprolol | 18 | $641 | $36 |
| Glipizide | 74 | $542 | $7 |
| Levoxyl | 19 | $453 | $24 |
| Simvastatin | 71 | $440 | $6 |
| Valsartan-Hydrochlorothiazide | 19 | $431 | $23 |
| Lisinopril | 105 | $430 | $4 |
| Enalapril Maleate | 15 | $396 | $26 |
| Alendronate | 59 | $349 | $6 |
| Calcitriol | 12 | $332 | $28 |
| Lovastatin | 19 | $211 | $11 |
| Pantoprazole | 13 | $188 | $14 |
| Spironolactone | 22 | $172 | $8 |
| Benazepril | 12 | $156 | $13 |
| Carvedilol | 14 | $93 | $7 |
| Amlodipine Besylate | 30 | $89 | $3 |
| Glimepiride | 14 | $64 | $5 |
2015: 51 drugs
| Lantus Solostar | 245 | $139,279 | $568 |
| Invokamet | 186 | $88,909 | $478 |
| Victoza 3-Pak | 93 | $72,546 | $780 |
| Januvia | 128 | $62,691 | $490 |
| Tradjenta | 120 | $56,386 | $470 |
| Levemir Flextouch | 99 | $55,490 | $561 |
| Trulicity | 71 | $50,378 | $710 |
| Jentadueto | 100 | $44,834 | $448 |
| Novolog Flexpen | 58 | $34,676 | $598 |
| Forteo | 17 | $32,410 | $1,906 |
| Invokana | 68 | $31,487 | $463 |
| Janumet | 45 | $28,526 | $634 |
| Lantus | 72 | $24,974 | $347 |
| Novolog | 36 | $19,934 | $554 |
| Humalog Kwikpen U-100 | 20 | $16,217 | $811 |
| Jardiance | 28 | $14,260 | $509 |
| Victoza 2-Pak | 33 | $13,768 | $417 |
| Tanzeum | 29 | $13,328 | $460 |
| Janumet Xr | 41 | $12,687 | $309 |
| Levemir | 27 | $12,498 | $463 |
| Bd Ultra-Fine Pen Needle | 178 | $10,576 | $59 |
| Zetia | 35 | $9,894 | $283 |
| Metformin Hcl Er | 42 | $8,571 | $204 |
| Crestor | 31 | $7,993 | $258 |
| Glyxambi | 13 | $6,541 | $503 |
| Kombiglyze Xr | 19 | $6,429 | $338 |
| Humalog | 12 | $6,049 | $504 |
| Onglyza | 13 | $5,936 | $457 |
| Synthroid | 109 | $4,459 | $41 |
| Vytorin | 13 | $3,721 | $286 |
| Repaglinide | 14 | $2,531 | $181 |
| Levothyroxine | 98 | $2,044 | $21 |
| Metformin | 262 | $2,026 | $8 |
| Atorvastatin | 80 | $1,135 | $14 |
| Valsartan-Hydrochlorothiazide | 17 | $662 | $39 |
| Metoprolol | 14 | $660 | $47 |
| Novofine 32 | 13 | $602 | $46 |
| Novotwist | 11 | $586 | $53 |
| Insulin | 16 | $574 | $36 |
| Insulin | 17 | $563 | $33 |
| Glipizide | 92 | $460 | $5 |
| Glipizide Er | 32 | $453 | $14 |
| Methimazole | 44 | $424 | $10 |
| Lisinopril | 105 | $370 | $4 |
| Simvastatin | 76 | $366 | $5 |
| Losartan | 36 | $268 | $7 |
| Amlodipine Besylate | 41 | $232 | $6 |
| Alendronate | 27 | $175 | $6 |
| Glimepiride | 33 | $145 | $4 |
| Carvedilol | 16 | $68 | $4 |
| Hydrochlorothiazide | 11 | $68 | $6 |
2014: 33 drugs
| Lantus Solostar | 201 | $83,840 | $417 |
| Victoza 3-Pak | 65 | $42,731 | $657 |
| Janumet | 72 | $29,149 | $405 |
| Lantus | 65 | $26,938 | $414 |
| Novolog Flexpen | 58 | $26,585 | $458 |
| Humalog | 47 | $25,169 | $536 |
| Januvia | 38 | $18,107 | $476 |
| Novolog | 34 | $14,427 | $424 |
| Victoza 2-Pak | 28 | $12,537 | $448 |
| Metformin Hcl Er | 54 | $10,834 | $201 |
| Tradjenta | 28 | $10,788 | $385 |
| Levemir Flextouch | 23 | $9,566 | $416 |
| Janumet Xr | 23 | $7,162 | $311 |
| Bd Ultra-Fine Pen Needle | 124 | $6,859 | $55 |
| Invokana | 18 | $6,809 | $378 |
| Glumetza | 13 | $6,486 | $499 |
| Onglyza | 19 | $5,822 | $306 |
| Levemir | 13 | $4,987 | $384 |
| Crestor | 22 | $4,829 | $220 |
| Jentadueto | 11 | $3,991 | $363 |
| Levemir Flexpen | 11 | $3,900 | $355 |
| Synthroid | 72 | $3,003 | $42 |
| Levothyroxine | 133 | $2,137 | $16 |
| Metformin | 150 | $1,260 | $8 |
| Pioglitazone | 11 | $574 | $52 |
| Insulin | 14 | $372 | $27 |
| Sure Comfort | 11 | $318 | $29 |
| Lisinopril | 57 | $303 | $5 |
| Glimepiride | 28 | $262 | $9 |
| Atorvastatin | 12 | $249 | $21 |
| Simvastatin | 27 | $248 | $9 |
| Glipizide | 30 | $207 | $7 |
| Methimazole | 20 | $141 | $7 |
2013: 19 drugs
| Lantus Solostar | 90 | $32,981 | $366 |
| Victoza 3-Pak | 42 | $20,873 | $497 |
| Novolog Flexpen | 49 | $20,690 | $422 |
| Janumet | 40 | $13,866 | $347 |
| Janumet Xr | 26 | $6,311 | $243 |
| Humalog | 13 | $5,159 | $397 |
| Synthroid | 121 | $4,721 | $39 |
| Levemir Flexpen | 12 | $4,718 | $393 |
| Tradjenta | 11 | $4,664 | $424 |
| Januvia | 11 | $2,937 | $267 |
| Bd Ultra-Fine Pen Needle | 47 | $2,635 | $56 |
| Crestor | 11 | $2,475 | $225 |
| Levothyroxine | 54 | $797 | $15 |
| Tirosint | 12 | $546 | $46 |
| Metformin | 47 | $437 | $9 |
| Liothyronine | 12 | $433 | $36 |
| Glimepiride | 16 | $126 | $8 |
| Lisinopril | 14 | $94 | $7 |
| Metformin Hcl Er | 14 | $83 | $6 |
Money from drug and device companies
$77,849 in 2025
| 2025 | 25 | 159 | $58,570 | $77,849 |
| 2024 | 22 | 133 | $11,430 | $17,523 |
| 2023 | 23 | 192 | $30,678 | $44,016 |
| 2022 | 24 | 195 | $20,414 | $27,346 |
| 2021 | 18 | 126 | $10,260 | $15,008 |
| 2020 | 17 | 162 | $19,361 | $23,584 |
| 2019 | 23 | 189 | $39,614 | $47,407 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Zepbound | $47,821 | 64 payments
|
| Alexion Pharmaceuticals | Strensiq | $25,195 | 22 payments
|
| Neurocrine BioSciences | Crenessity | $3,381 | 6 payments
|
| Amgen | Tepezza | $393 | 18 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $156 | 7 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $135 | 9 payments
|
See all 159 published payments
| Amgen | Meals · 2025-12-17 | Tepezza | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-12-10 | Rezdiffra | $18 |
| Lilly USA | Meals · 2025-12-04 | Jardiance | $5 |
| Acella Pharmaceuticals | Meals · 2025-12-03 | NP Thyroid 60 | $26 |
| Dexcom | Meals · 2025-12-03 | Dexcom G6 Transmitter | $27 |
| Amgen | Meals · 2025-11-25 | Repatha | $21 |
| Amgen | Meals · 2025-11-19 | Tepezza | $27 |
| Madrigal Pharmaceuticals | Meals · 2025-11-19 | Rezdiffra | $19 |
| Neurocrine BioSciences | Consulting · 2025-11-15 | Crenessity | $3,200 |
| Neurocrine BioSciences | Meals · 2025-11-15 | Crenessity | $59 |
| Neurocrine BioSciences | Meals · 2025-11-15 | Crenessity | $48 |
| Neurocrine BioSciences | Meals · 2025-11-15 | Crenessity | $27 |
| Lilly USA | Paid to speak or teach · 2025-11-12 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-11-12 | Zepbound | $1,100 |
| Recordati Rare Diseases Inc. | Meals · 2025-11-11 | Isturisa | $24 |
| Tandem Diabetes Care | Meals · 2025-11-11 | T:Slim X2 Insulin Pump With Control-Iq | $16 |
| Amgen | Meals · 2025-10-29 | Tepezza | $17 |
| Madrigal Pharmaceuticals | Meals · 2025-10-28 | Rezdiffra | $27 |
| Lilly USA | Meals · 2025-10-23 | Mounjaro | $28 |
| Lilly USA | Meals · 2025-10-20 | Mounjaro | $26 |
| Lilly USA | Meals · 2025-10-15 | Jardiance | $34 |
| Amgen | Meals · 2025-10-15 | Tepezza | $20 |
| Tandem Diabetes Care | Meals · 2025-10-15 | T:Slim X2 Insulin Pump With Control-Iq | $20 |
| Amgen | Meals · 2025-10-08 | Repatha | $26 |
| Madrigal Pharmaceuticals | Meals · 2025-10-08 | Rezdiffra | $44 |
| Radius Health | Meals · 2025-09-24 | Tymlos | $32 |
| Dexcom | Meals · 2025-09-24 | Dexcom G6 Transmitter | $40 |
| Lilly USA | Paid to speak or teach · 2025-09-18 | Zepbound | $2,200 |
| Lilly USA | Paid to speak or teach · 2025-09-18 | Zepbound | $825 |
| Alexion Pharmaceuticals | Paid to speak or teach · 2025-09-18 | None | $1,080 |
| Alexion Pharmaceuticals | Paid to speak or teach · 2025-09-18 | None | $2,880 |
| Amgen | Meals · 2025-09-16 | Tepezza | $30 |
| Lilly USA | Meals · 2025-09-15 | Zepbound | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-11 | Kerendia | $23 |
| Ascendis Pharma Endocrinology | Meals · 2025-09-10 | Yorvipath | $28 |
| Alexion Pharmaceuticals | Travel · 2025-09-05 | None | $41 |
| Alexion Pharmaceuticals | Travel · 2025-09-05 | None | $94 |
| Alexion Pharmaceuticals | Meals · 2025-09-05 | None | $16 |
| Alexion Pharmaceuticals | Travel · 2025-09-05 | None | $197 |
| Alexion Pharmaceuticals | Meals · 2025-09-05 | None | $6 |
| Alexion Pharmaceuticals | Travel · 2025-09-05 | None | $34 |
| Alexion Pharmaceuticals | Travel · 2025-09-04 | None | $883 |
| Alexion Pharmaceuticals | Travel · 2025-09-04 | None | $658 |
| Corcept Therapeutics | Meals · 2025-09-03 | Korlym | $28 |
| Lilly USA | Meals · 2025-08-28 | Jardiance | $24 |
| Lilly USA | Paid to speak or teach · 2025-08-27 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-08-26 | Zepbound | $825 |
| Lilly USA | Paid to speak or teach · 2025-08-26 | Zepbound | $2,200 |
| Alexion Pharmaceuticals | Meals · 2025-08-26 | Strensiq | $14 |
| Medtronic | Meals · 2025-08-26 | Minimed 780g | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-26 | Jardiance | $25 |
| Lilly USA | Meals · 2025-08-21 | Zepbound | $33 |
| Lilly USA | Meals · 2025-08-20 | Mounjaro | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-20 | Kerendia | $14 |
| Sequel Med Tech | Meals · 2025-08-20 | Twiist | $21 |
| Amgen | Meals · 2025-08-19 | Repatha | $20 |
| Lilly USA | Paid to speak or teach · 2025-07-24 | Zepbound | $1,100 |
| Lilly USA | Meals · 2025-07-16 | Mounjaro | $32 |
| Lilly USA | Meals · 2025-07-14 | Zepbound | $34 |
| Lilly USA | Meals · 2025-07-14 | Zepbound | $34 |
| Lilly USA | Paid to speak or teach · 2025-07-14 | Zepbound | $1,100 |
| Lilly USA | Meals · 2025-07-14 | Zepbound | $14 |
| Lilly USA | Travel · 2025-07-14 | Zepbound | $97 |
| Alexion Pharmaceuticals | Meals · 2025-07-13 | Strensiq | $118 |
| Lilly USA | Paid to speak or teach · 2025-07-09 | Zepbound | $1,100 |
| Madrigal Pharmaceuticals | Meals · 2025-07-08 | Rezdiffra | $10 |
| Xeris Pharmaceuticals | Meals · 2025-07-08 | Recorlev | $20 |
| Verity Pharmaceuticals | Meals · 2025-07-01 | Tlando | $18 |
| Lilly USA | Paid to speak or teach · 2025-06-26 | Zepbound | $1,100 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-26 | Kerendia | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-26 | Kerendia | $9 |
| Lilly USA | Meals · 2025-06-24 | Mounjaro | $33 |
| Lilly USA | Meals · 2025-06-20 | Jardiance | $23 |
| Alvogen | Meals · 2025-06-18 | Teriparatide | $22 |
| Madrigal Pharmaceuticals | Meals · 2025-06-17 | Rezdiffra | $13 |
| Radius Health | Meals · 2025-06-17 | Tymlos | $32 |
| Recordati Rare Diseases Inc. | Meals · 2025-06-10 | Isturisa | $16 |
| Lilly USA | Paid to speak or teach · 2025-06-10 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-06-10 | Zepbound | $1,100 |
| Lilly USA | Meals · 2025-06-04 | Mounjaro | $30 |
| Alexion Pharmaceuticals | Meals · 2025-06-03 | Strensiq | $7 |
| Alexion Pharmaceuticals | Consulting · 2025-06-03 | Strensiq | $5,040 |
| Alexion Pharmaceuticals | Travel · 2025-06-03 | Strensiq | $239 |
| Lilly USA | Paid to speak or teach · 2025-05-28 | Zepbound | $1,100 |
| Amgen | Meals · 2025-05-28 | Repatha | $20 |
| Ascendis Pharma Endocrinology | Meals · 2025-05-28 | Yorvipath | $19 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-22 | Kerendia | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-22 | Kerendia | $2 |
| Lilly USA | Paid to speak or teach · 2025-05-20 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-05-20 | Zepbound | $1,100 |
| Amgen | Meals · 2025-05-20 | Evenity | $9 |
| Amgen | Meals · 2025-05-20 | Tepezza | $25 |
| Lilly USA | Paid to speak or teach · 2025-05-19 | Zepbound | $1,925 |
| Lilly USA | Paid to speak or teach · 2025-05-19 | Zepbound | $2,200 |
| Madrigal Pharmaceuticals | Meals · 2025-05-19 | Rezdiffra | $25 |
| Lilly USA | Meals · 2025-05-15 | Zepbound | $125 |
| Lilly USA | Travel · 2025-05-15 | None | $263 |
| Lilly USA | Travel · 2025-05-15 | None | $624 |
| Lilly USA | Paid to speak or teach · 2025-05-14 | Zepbound | $1,100 |
| Neurocrine BioSciences | Meals · 2025-05-14 | Crenessity | $26 |
| Lilly USA | Paid to speak or teach · 2025-05-12 | Zepbound | $825 |
| Lilly USA | Paid to speak or teach · 2025-05-12 | Zepbound | $2,200 |
| Alexion Pharmaceuticals | Travel · 2025-05-11 | Strensiq | $1,083 |
| Lilly USA | Meals · 2025-05-10 | Jardiance | $32 |
| Alexion Pharmaceuticals | Meals · 2025-05-10 | None | $62 |
| Abbott Laboratories | Meals · 2025-05-09 | Freestyle Libre 3 | $14 |
| Lilly USA | Meals · 2025-05-08 | Zepbound | $34 |
| Alexion Pharmaceuticals | Travel · 2025-05-08 | Strensiq | $11,975 |
| Lilly USA | Paid to speak or teach · 2025-04-30 | Zepbound | $1,100 |
| Recordati Rare Diseases Inc. | Meals · 2025-04-29 | Signifor Lar | $27 |
| Antares Pharma | Meals · 2025-04-29 | Xyosted | $14 |
| Amgen | Meals · 2025-04-24 | Tepezza | $12 |
| Lilly USA | Paid to speak or teach · 2025-04-15 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-04-14 | Zepbound | $1,100 |
| Lilly USA | Meals · 2025-04-09 | Mounjaro | $13 |
| Abbvie | Meals · 2025-04-08 | Ubrelvy | $26 |
| Lilly USA | Paid to speak or teach · 2025-04-07 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-04-02 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-04-01 | Zepbound | $1,100 |
| Lilly USA | Paid to speak or teach · 2025-03-31 | Zepbound | $1,100 |
| Revance Therapeutics | Meals · 2025-03-28 | None | $25 |
| Revance Therapeutics | Meals · 2025-03-28 | None | $24 |
| Lilly USA | Paid to speak or teach · 2025-03-26 | Zepbound | $1,100 |
| Astellas Pharma US | Meals · 2025-03-26 | Veozah | $31 |
| Lilly USA | Meals · 2025-03-25 | Jardiance | $32 |
| Lilly USA | Paid to speak or teach · 2025-03-24 | Zepbound | $1,100 |
| Radius Health | Meals · 2025-03-19 | Tymlos | $31 |
| Lilly USA | Meals · 2025-03-18 | Mounjaro | $22 |
| Lilly USA | Paid to speak or teach · 2025-03-12 | Zepbound | $1,100 |
| Alexion Pharmaceuticals | Meals · 2025-03-12 | Strensiq | $2 |
| Alexion Pharmaceuticals | Meals · 2025-03-12 | Strensiq | $26 |
| Astellas Pharma US | Meals · 2025-03-12 | Veozah | $30 |
| Lilly USA | Paid to speak or teach · 2025-03-11 | Zepbound | $5,500 |
| Lilly USA | Paid to speak or teach · 2025-03-11 | Zepbound | $550 |
| Lilly USA | Paid to speak or teach · 2025-03-10 | Zepbound | $1,100 |
| Lilly USA | Meals · 2025-03-06 | Mounjaro | $16 |
| Sanofi-Aventis U.S. | Meals · 2025-02-26 | Tzield | $17 |
| Amgen | Meals · 2025-02-25 | Evenity | $29 |
| Alexion Pharmaceuticals | Paid to speak or teach · 2025-02-20 | None | $720 |
| Lilly USA | Meals · 2025-02-19 | Jardiance | $19 |
| Amgen | Meals · 2025-02-19 | Tepezza | $28 |
| Amgen | Meals · 2025-02-12 | Repatha | $11 |
| Alexion Pharmaceuticals | Meals · 2025-02-11 | Strensiq | $19 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-06 | Kerendia | $1 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-06 | Kerendia | $30 |
| Neurocrine BioSciences | Meals · 2025-02-04 | Crenessity | $21 |
| Revance Therapeutics | Meals · 2025-02-04 | Daxi | $14 |
| Lilly USA | Meals · 2025-01-29 | Mounjaro | $29 |
| Ascendis Pharma Endocrinology | Meals · 2025-01-29 | Yorvipath | $25 |
| Lilly USA | Travel · 2025-01-23 | None | $259 |
| Lilly USA | Travel · 2025-01-23 | None | $195 |
| Acella Pharmaceuticals | Meals · 2025-01-22 | NP Thyroid 60 | $20 |
| Recordati Rare Diseases Inc. | Meals · 2025-01-21 | Isturisa | $15 |
| Lilly USA | Meals · 2025-01-15 | Mounjaro | $13 |
| Amgen | Meals · 2025-01-08 | Tepezza | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-07 | Kerendia | $11 |
| Amgen | Meals · 2025-01-07 | Evenity | $29 |
| Antares Pharma | Meals · 2025-01-07 | Xyosted | $20 |
| Amgen | Meals · 2025-01-06 | Tepezza | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $17,523
| Alexion Pharmaceuticals | Strensiq | $15,607 | 38 payments
|
| Lilly USA | Mounjaro | $507 | 20 payments
|
| Amgen | Tepezza | $287 | 18 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $194 | 14 payments
|
| Radius Health | Tymlos | $122 | 5 payments
|
| Dexcom | Dexcom G6 Transmitter | $98 | 3 payments
|
| Beta Bionics | Ilet Bionic Pancreas | $97 | 4 payments
|
| Merz North America | Xeomin | $78 | 4 payments
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $74 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $72 | 3 payments
|
| Abbott Laboratories | Freestyle Insulinx | $57 | 3 payments
|
| Recordati Rare Diseases Inc. | Signifor Lar | $48 | 2 payments
|
| Corcept Therapeutics | Korlym | $47 | 2 payments
|
| Mannkind | Afrezza | $46 | 2 payments
|
| Sanofi-Aventis U.S. | Tzield | $34 | 2 payments
|
| Astellas Pharma US | Veozah | $30 | 1 payment
|
| Neurocrine Biosciences | None | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $25 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $23 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $19 | 1 payment
|
| Pfizer | Paxlovid | $18 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $15 | 1 payment
|
2023: $44,016
| Alexion Pharmaceuticals | Strensiq | $22,648 | 36 payments
|
| Corcept Therapeutics | Korlym | $19,101 | 36 payments
|
| Lilly USA | Mounjaro | $333 | 16 payments
|
| Merz North America | Xeomin | $308 | 5 payments
|
| Amgen | Evenity | $271 | 13 payments
|
| Novo Nordisk | Ozempic | $251 | 32 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $229 | 11 payments
|
| Dexcom | Dexcom G6 Transmitter | $185 | 7 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $171 | 14 payments
|
| Medtronic | Minimed 780g | $79 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $66 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $55 | 3 payments
|
| Kyowa Kirin | Crysvita | $48 | 2 payments
|
| MannKind | Afrezza | $46 | 2 payments
|
| Embecta | Bd Nano 2nd Gen Pen Needle | $40 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $38 | 2 payments
|
| Radius Health | Tymlos | $27 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $26 | 1 payment
|
| RGH Enterprises | None | $23 | 1 payment
|
| Xeris Pharmaceuticals | Recorlev | $22 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $17 | 1 payment
|
| Currax Pharmaceuticals | Contrave | $16 | 1 payment
|
| AbbVie | Ubrelvy | $15 | 1 payment
|
2022: $27,346
| Corcept Therapeutics | Korlym | $17,447 | 37 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $5,172 | 18 payments
|
| Novo Nordisk | Rybelsus | $2,558 | 54 payments
|
| Alexion Pharmaceuticals | Strensiq | $727 | 7 payments
|
| Lilly USA | Mounjaro | $393 | 20 payments
|
| Amgen | Repatha | $325 | 15 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $137 | 12 payments
|
| Dexcom | Dexcom G6 Transmitter | $66 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $64 | 3 payments
|
| IBSA Pharma | Tirosint | $55 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $46 | 2 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $46 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $43 | 3 payments
|
| Mannkind | Afrezza | $43 | 2 payments
|
| Merck Sharp & Dohme | Steglatro | $35 | 2 payments
|
| BioMarin Pharmaceutical | Palynziq | $34 | 1 payment
|
| Becton Dickinson and | Bd Nano 2nd Gen Pen Needle | $34 | 1 payment
|
| Radius Health | Tymlos | $29 | 1 payment
|
| Bigfoot Biomedical | Unity Diabetes Management System | $24 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $21 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $13 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $12 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $12 | 1 payment
|
| CeQur | Cequr Simplicity | $10 | 1 payment
|
2021: $15,008
| Corcept Therapeutics | Korlym | $11,498 | 29 payments
|
| Alexion Pharmaceuticals | Strensiq | $1,923 | 6 payments
|
| Lilly USA | Trulicity | $305 | 20 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $240 | 15 payments
|
| Amgen | Evenity | $235 | 10 payments
|
| Novo Nordisk | Ozempic | $179 | 14 payments
|
| Merck Sharp & Dohme | Januvia | $122 | 8 payments
|
| MannKind | Afrezza | $79 | 3 payments
|
| Xeris Pharmaceuticals | Gvoke Pfs | $76 | 4 payments
|
| IBSA Pharma | Tirosint | $61 | 3 payments
|
| AbbVie | Synthroid | $57 | 2 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $56 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $54 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $42 | 2 payments
|
| Medtronic | Inpen | $30 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $15 | 1 payment
|
| Amarin Pharma | Vascepa | $13 | 1 payment
|
2020: $23,584
| Corcept Therapeutics | Korlym | $10,616 | 32 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $5,157 | 7 payments
|
| Alexion Pharmaceuticals | Strensiq | $3,689 | 8 payments
|
| Janssen Pharmaceuticals | Invokana | $2,857 | 20 payments
|
| Novo Nordisk | Ozempic | $428 | 42 payments
|
| Amgen | Evenity | $198 | 12 payments
|
| Amarin Pharma | Vascepa | $121 | 7 payments
|
| Xeris Pharmaceuticals | Gvoke Pfs | $76 | 4 payments
|
| Radius Health | Tymlos | $73 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $67 | 4 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $57 | 3 payments
|
| Mannkind | Afrezza | $55 | 3 payments
|
| AbbVie | Synthroid | $54 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $43 | 2 payments
|
| Vivus | Qsymia | $42 | 2 payments
|
| GlaxoSmithKline | Anoro Ellipta | $25 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $24 | 1 payment
|
2019: $47,407
| Corcept Therapeutics | Korlym | $15,806 | 32 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $11,524 | 17 payments
|
| Alexion Pharmaceuticals | Strensiq | $11,004 | 19 payments
|
| Janssen Pharmaceuticals | Invokana | $7,662 | 13 payments
|
| Lilly USA | Trulicity | $305 | 17 payments
|
| Novo Nordisk | Ozempic | $305 | 30 payments
|
| Mannkind | Afrezza | $140 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $93 | 4 payments
|
| Shire North American Group | Natpara (Parathyroid Hormone) | $87 | 5 payments
|
| Radius Health | Tymlos | $64 | 2 payments
|
| Amgen | Repatha | $50 | 3 payments
|
| Sanofi-Aventis U.S. | Toujeo | $49 | 2 payments
|
| Vivus | Qsymia | $44 | 2 payments
|
| IBSA Pharma | Tirosint | $44 | 2 payments
|
| Abbott Laboratories | Freestyle Libre Pro | $37 | 3 payments
|
| Nalpropion Pharmaceuticals | Contrave | $35 | 2 payments
|
| Merck Sharp & Dohme | Januvia | $31 | 2 payments
|
| Insulet | Omnipod | $30 | 2 payments
|
| Horizon Therapeutics plc | None | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $20 | 1 payment
|
| AbbVie | Synthroid | $18 | 1 payment
|
| Companion Medical | Inpen | $17 | 1 payment
|
| LifeScan | Onetouch | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2022 | Their institution | $553,181 |
| Eli Lilly and Company · A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk · 2019 | This clinician | $514,787 |
| Eli Lilly and Company · A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk · 2019 | Their institution | $492,493 |
| Eli Lilly and Company · A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk · 2020 | Their institution | $491,633 |
| AstraZeneca UK Limited · A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of Azd5718 in Participants With Proteinuric Chronic Kidney Disease · 2021 | Their institution | $285,478 |
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2021 | Their institution | $270,318 |
| Eli Lilly and Company · A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk · 2021 | Their institution | $160,966 |
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2023 | Their institution | $147,794 |
| SANOFI-AVENTIS U.S. LLC · A 26-Week Randomized, Open-Label, Active-Controlled, 2-Treatment Arm, Parallel Group Multi-Center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers · 2019 | This clinician | $142,095 |
| Eli Lilly and Company · A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) · 2023 | Their institution | $138,351 |
| Eli Lilly and Company · A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) · 2024 | Their institution | $132,136 |
| Novo Nordisk AS · Ozempic · 2022 | Their institution | $91,385 |
| Novo Nordisk AS · Ozempic · 2023 | Their institution | $63,635 |
| AstraZeneca UK Limited · A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of Azd5718 in Participants With Proteinuric Chronic Kidney Disease · 2023 | Their institution | $39,823 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Multicentre, Double-Blind Study To Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin Fdc Compared To Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria · 2024 | Their institution | $23,396 |
| AstraZeneca UK Limited · A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of Azd5718 in Participants With Proteinuric Chronic Kidney Disease · 2022 | Their institution | $18,937 |
| AstraZeneca Pharmaceuticals LP · The Purpose of the D4325c00007 Study Is To Identify and Characterise Patients With Known Or Newly Diagnosed Ckd for Possible Participation in Future Renal Clinical Studies and To Obtain An Overview on Current Treatment Choices for This Patient Group in Different Regions · 2024 | Their institution | $17,674 |
| AstraZeneca Pharmaceuticals LP · The Purpose of the D4325c00007 Study Is To Identify and Characterise Patients With Known Or Newly Diagnosed Ckd for Possible Participation in Future Renal Clinical Studies and To Obtain An Overview on Current Treatment Choices for This Patient Group in Different Regions · 2024 | This clinician | $17,674 |
| PFIZER INC. · A Phase 23 Randomized Doubleblind Placebocontrolled Parallelgroup Study With Lotiglipron Pf07081532 To Assess Cardiovascular and Other Longterm Outcomes in Adults With Type 2 Diabetes Mellitus · 2023 | Their institution | $15,200 |
| SANOFI US SERVICES INC. · A 26-Week Randomized, Open-Label, Active-Controlled, 2-Treatment Arm, Parallel Group Multi-Center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers · 2019 | This clinician | $13,700 |
| AstraZeneca Pharmaceuticals LP · A Phase 3,Randomised,Double Blind,Active Controlled Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Ckd Progression in Participants With Ckd and High Blood Pressure · 2024 | Their institution | $3,500 |
| Eli Lilly and Company · A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk · 2020 | This clinician | $3,207 |
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2020 | Their institution | $1,502 |
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2024 | Their institution | $480 |
| Eli Lilly and Company · A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) · 2023 | This clinician | $195 |
| Eli Lilly and Company · The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) · 2025 | Their institution | $19 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1558535203
- Licence
- CA A127054California A127054: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 220 Standiford Ave Ste F, Modesto, CA, 95350
- NPI first listed
- 2008-04-14
- NPI last updated
- 2021-07-27
- NPI record certified
- 2021-07-27
This is when the NPI record was last certified, not a medical board exam.